Summary

The 7 major hidradenitis suppurativa markets reached a value of US$ 1.4 Billion in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 3.9 Billion by 2034, exhibiting a growth rate (CAGR) of 9.79% during 2024-2034.

The hidradenitis suppurativa market has been comprehensively analyzed in IMARC's new report titled "Hidradenitis Suppurativa Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Hidradenitis suppurativa, also referred to as acne inversus, is a chronic, painful inflammatory skin condition that causes lumps to develop beneath the skin. These lumps generally form in areas where the skin rubs against itself, such as the groin, armpits, breasts, and buttocks. The condition tends to remain for an extended period and worsen over time, seriously affecting everyday life and emotional health. Individuals suffering from hidradenitis suppurativa may experience painful pea-sized lumps, leaking bumps or sores, blackheads, and tunnels under the skin. The other common symptoms include abscess, excessive sweating, body odor, itching, pimples, pus, swelling, etc. In severe cases, the disease can lead to significant discomfort, reduced mobility, and impaired quality of life. The diagnosis of this ailment is mainly based on medical history and the underlying symptoms. The healthcare professional may examine the affected skin region and sometimes test an infected part's sample. Additionally, various diagnostic procedures, such as ultrasound, magnetic resonance imaging (MRI), biopsy, etc., are further required to identify the extent of the disease.

The rising incidences of blocked hair follicles caused by several risk factors, including hormonal imbalances like polycystic ovarian syndrome, bacterial colonization, obesity, etc., are primarily driving the hidradenitis suppurativa market. Moreover, the increasing prevalence of genetic disorders that alter cell structure and cause immune dysfunction is further augmenting the market growth. Apart from this, the widespread adoption of antiandrogen therapy with spironolactone for treating the ailment, since it inhibits androgens from binding to androgen receptors and prevents cancer cells from growing, is acting as another growth-inducing factor. Furthermore, the inflating utilization of biologics, such as TNF-alpha inhibitors, which relieve disease symptoms by blocking the signaling pathway of a protein involved in the inflammatory process, is also bolstering the market growth. Additionally, several key players are making significant investments in developing imaging techniques that can help identify the extent and severity of the disease and can be particularly useful for assessing deep-seated lesions. This, in turn, is further creating a positive outlook for the market. Moreover, the escalating demand for advanced surgical procedures, such as cryoinsufflation, to effectively treat smaller lesions, especially those in areas where surgery may be difficult or for patients who cannot tolerate more invasive procedures, is also expected to bolster the hidradenitis suppurativa market in the coming years.

IMARC Group's new report provides an exhaustive analysis of the hidradenitis suppurativa market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for hidradenitis suppurativa and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the hidradenitis suppurativa market in any manner.

Time Period of the Study

Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034

Countries Covered

United States
Germany
France
United Kingdom
Italy
Spain
Japan

Analysis Covered Across Each Country

Historical, current, and future epidemiology scenario
Historical, current, and future performance of the hidradenitis suppurativa market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the hidradenitis suppurativa market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current hidradenitis suppurativa marketed drugs and late-stage pipeline drugs.

In-Market Drugs

Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance

Late-Stage Pipeline Drugs

Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:
Market Insights

How has the hidradenitis suppurativa market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the hidradenitis suppurativa market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the hidradenitis suppurativa market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?

Epidemiology Insights

What is the number of prevalent cases (​2018-2034​) of hidradenitis suppurativa across the seven major markets?
What is the number of prevalent cases (​2018-2034​) of hidradenitis suppurativa by age across the seven major markets?
What is the number of prevalent cases (​2018-2034​) of hidradenitis suppurativa by gender across the seven major markets?
How many patients are diagnosed (​2018-2034​) with hidradenitis suppurativa across the seven major markets?
What is the size of the hidradenitis suppurativa patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of hidradenitis suppurativa?
What will be the growth rate of patients across the seven major markets?

Hidradenitis Suppurativa: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for hidradenitis suppurativa drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the hidradenitis suppurativa market?
What are the key regulatory events related to the hidradenitis suppurativa market?
What is the structure of clinical trial landscape by status related to the hidradenitis suppurativa market?
What is the structure of clinical trial landscape by phase related to the hidradenitis suppurativa market?
What is the structure of clinical trial landscape by route of administration related to the hidradenitis suppurativa market?

ページTOPに戻る

Table of Contents

1 Preface

2 Scope and Methodology
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology

3 Executive Summary

4 Hidradenitis Suppurativa - Introduction
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence

5 Hidradenitis Suppurativa - Disease Overview
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment

6 Patient Journey

7 Hidradenitis Suppurativa - Epidemiology and Patient Population
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (​2018-2034​)
7.2.4 Epidemiology by Gender (​2018-2034​)
7.2.5 Diagnosed Cases (​2018-2034​)
7.2.6 Patient Pool/Treated Cases (​2018-2034​)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (​2018-2034​)
7.3.4 Epidemiology by Gender (​2018-2034​)
7.3.5 Diagnosed Cases (​2018-2034​)
7.3.6 Patient Pool/Treated Cases (​2018-2034​)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (​2018-2034​)
7.4.4 Epidemiology by Gender (​2018-2034​)
7.4.5 Diagnosed Cases (​2018-2034​)
7.4.6 Patient Pool/Treated Cases (​2018-2034​)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (​2018-2034​)
7.5.4 Epidemiology by Gender (​2018-2034​)
7.5.5 Diagnosed Cases (​2018-2034​)
7.5.6 Patient Pool/Treated Cases (​2018-2034​)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (​2018-2034​)
7.6.4 Epidemiology by Gender (​2018-2034​)
7.6.5 Diagnosed Cases (​2018-2034​)
7.6.6 Patient Pool/Treated Cases (​2018-2034​)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (​2018-2034​)
7.7.4 Epidemiology by Gender (​2018-2034​)
7.7.5 Diagnosed Cases (​2018-2034​)
7.7.6 Patient Pool/Treated Cases (​2018-2034​)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (​2018-2034​)
7.8.4 Epidemiology by Gender (​2018-2034​)
7.8.5 Diagnosed Cases (​2018-2034​)
7.8.6 Patient Pool/Treated Cases (​2018-2034​)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (​2018-2034​)
7.9.4 Epidemiology by Gender (​2018-2034​)
7.9.5 Diagnosed Cases (​2018-2034​)
7.9.6 Patient Pool/Treated Cases (​2018-2034​)

8 Hidradenitis Suppurativa - Treatment Algorithm, Guidelines, and Medical Practices
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm

9 Hidradenitis Suppurativa - Unmet Needs

10 Hidradenitis Suppurativa - Key Endpoints of Treatment

11 Hidradenitis Suppurativa - Marketed Products
11.1 List of Hidradenitis Suppurativa Marketed Drugs Across the Top 7 Markets
11.1.1 Humira (Adalimumab) - AbbVie/AstraZeneca
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets

Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.

12 Hidradenitis Suppurativa - Pipeline Drugs
12.1 List of Hidradenitis Suppurativa Pipeline Drugs Across the Top 7 Markets
12.1.1 Bermekimab - Janssen Biotech
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
12.1.2 Lutikizumab - AbbVie
12.1.2.1 Drug Overview
12.1.2.2 Mechanism of Action
12.1.2.3 Clinical Trial Results
12.1.2.4 Safety and Efficacy
12.1.2.5 Regulatory Status
12.1.3 Bimekizumab - UCB
12.1.3.1 Drug Overview
12.1.3.2 Mechanism of Action
12.1.3.3 Clinical Trial Results
12.1.3.4 Safety and Efficacy
12.1.3.5 Regulatory Status
12.1.4 Secukinumab - Novartis
12.1.4.1 Drug Overview
12.1.4.2 Mechanism of Action
12.1.4.3 Clinical Trial Results
12.1.4.4 Safety and Efficacy
12.1.4.5 Regulatory Status
12.1.5 Povorcitinib - Incyte Corporation
12.1.5.1 Drug Overview
12.1.5.2 Mechanism of Action
12.1.5.3 Clinical Trial Results
12.1.5.4 Safety and Efficacy
12.1.5.5 Regulatory Status

Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.

13. Hidradenitis Suppurativa - Attribute Analysis of Key Marketed and Pipeline Drugs

14. Hidradenitis Suppurativa – Clinical Trial Landscape
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events

15 Hidradenitis Suppurativa - Market Scenario
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Hidradenitis Suppurativa - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Hidradenitis Suppurativa - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Hidradenitis Suppurativa - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Hidradenitis Suppurativa - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Hidradenitis Suppurativa - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Hidradenitis Suppurativa - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Hidradenitis Suppurativa - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Hidradenitis Suppurativa - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Hidradenitis Suppurativa - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Hidradenitis Suppurativa - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Hidradenitis Suppurativa - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Hidradenitis Suppurativa - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Hidradenitis Suppurativa - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Hidradenitis Suppurativa - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Hidradenitis Suppurativa - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Hidradenitis Suppurativa - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Hidradenitis Suppurativa - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Hidradenitis Suppurativa - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Hidradenitis Suppurativa - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Hidradenitis Suppurativa - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Hidradenitis Suppurativa - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Hidradenitis Suppurativa - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Hidradenitis Suppurativa - Access and Reimbursement Overview

16 Hidradenitis Suppurativa - Recent Events and Inputs From Key Opinion Leaders

17 Hidradenitis Suppurativa Market - SWOT Analysis
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats

18 Hidradenitis Suppurativa Market – Strategic Recommendations

19 Appendix